Inebilizumab

伊奈利珠单抗

Report date: 2026/05/22 20:01:29
First In Class

Base Information

Drug NameInebilizumab
Drug Alias Nameinebilizumabum伊奈利组单抗英比利珠单抗A-fucosylated anti-CD19 antibodyinebilizumab +[15] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsImmunoglobulin G4-Related DiseaseScleroderma, SystemicEncephalitis +[13] 
Global Approved IndicationsNeuromyelitis Optica
Approved Indications in ChinaNeuromyelitis Optica
Original Approved Country/TerritoryUnited States
Original Approved Date2020/06/11
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDuke UniversityHorizon Therapeutics PLC
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityHorizon Therapeutics Ireland DacHansoh Pharmaceutical Group Company Ltd +[11] 
Inactive CompaniesAstrazeneca PlcMedimmune LlcMedimmune Pharma Bv +[5] 
Active IndicationsImmunoglobulin G4-Related DiseaseScleroderma, SystemicEncephalitis +[6] 
Inactive IndicationsMultiple SclerosisHematologic NeoplasmsLymphoma, Large B-Cell, Diffuse +[7] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG